FDA Approves ConcizuTrace™ ELISA Companion Diagnostic for 2024 Concizumab Therapy in Hemophilia
The National Bleeding Disorders Foundation (NBDF) shared a post on X:
”The FDA has approved the ConcizuTrace™ ELISA Companion Diagnostic test to measure concizumab-mtci levels in hemophilia A and B patients.’
To learn more about this advancement, follow the link.
The U.S. Food and Drug Administration (FDA) has approved the ConcizuTrace™ ELISA Companion Diagnostic, a test designed to measure plasma levels of concizumab-mtci in patients with hemophilia A or B.
Concizumab-mtci is a subcutaneous therapy indicated for routine prophylaxis to prevent or reduce bleeding episodes in adult and pediatric patients (≥12 years) with hemophilia A with factor VIII inhibitors or hemophilia B with factor IX inhibitors.
The approval of this companion diagnostic marks a significant step in personalizing treatment, enabling clinicians to monitor drug exposure and potentially optimize therapeutic outcomes.
Never miss the important in the World of Hemophilia, read Hemostasis Today.
-
May 27, 2026, 17:51Nita Radhakrishnan: Post Graduate Institute of Child Health Receives WFH Data Quality Certification for Excellence
-
May 27, 2026, 17:51Fiona Robinson: What exactly Are Rebalancing Agents for Bleeding Aisorders?
-
May 27, 2026, 17:14Khurram Nasir: Can Earlier LDL-C Lowering Change the Trajectory of Cardiovascular Disease?
-
May 27, 2026, 17:09Yvonne Jongejan: Allele-Selective Silencing Therapy for VWD and Thrombotic Disorders
-
May 27, 2026, 16:58Catherine Moran: Important Step Forward as 1st WHO Resolution on Stroke Gets Adopted at WHA79
-
May 27, 2026, 16:08Heghine Khachatryan: Thrombosis in Oncology Remains a Major Healthcare Burden
-
May 27, 2026, 16:00Revealing Critical Gaps in Hemophilia Diagnosis and Access to Care in India – WFH
-
May 27, 2026, 16:00Melissa Hollo: Women Deserve Proactive Care, Not Reactive Care
-
May 27, 2026, 15:59Piotr Czempik: First Report of ROTEM Findings in Triple-Positive APS and Hageman Anomaly